Alpelisib trials for Breast cancer

All Alpelisib trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Alpelisib for Breast cancer

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
  NCT05646862 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 210 locations
• Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
  NCT05933395 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  NCT05564377 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 482 locations

Common questions

How many trials study Alpelisib for Breast cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.